OLMA实时信号 | 通过Getagraph.com最大化利润

购买 108004 min ago

@ $15.41

发出时间: 15 Feb 2024 @ 00:19

回报率: -34.26%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: -3.51 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:19):

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers...

Stats
今日成交量	63 207.00
平均成交量	831 451
市值	566.42M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.530 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.73
ATR14	$0.0160 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Harmon Cyrus	Sell	20 000	Common Stock
2024-03-18	Zojwalla Naseem	Sell	13 700	Stock Option (Right to Buy)
2024-03-18	Zojwalla Naseem	Buy	13 700	Common Stock
2024-03-05	Rappaport Andrew	Buy	385 965	Common Stock
2024-03-05	Rappaport Andrew	Sell	481 014	Common Stock

INSIDER POWER
66.26
Last 96 transactions
Buy: 6 282 820 \| Sell: 988 788

音量相关性

長: -0.38 (neutral)

短: 0.33 (neutral)

Signal:(42.438) Neutral

Olema Pharmaceuticals, 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Olema Pharmaceuticals, 相关性 - 货币/商品

-0.49
( neutral )

-0.46
( neutral )

0.00
( neutral )

0.11
( neutral )

0.16
( neutral )

0.44
( neutral )

Olema Pharmaceuticals, 财务报表

Annual	2023
营收:	$0
毛利润:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2023
营收:	$0
毛利润:	$-377 000 (0.00 %)
EPS:	$-2.14

FY	2022
营收:	$0
毛利润:	$-1.66M (0.00 %)
EPS:	$-2.56

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.795

Financial Reports:

No articles found.

Olema Pharmaceuticals,

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.